HIV/TB Roadmap at CROI 2018

Sunday, March 4, 2018

WHO Organized CROI-Affiliated events

Tackling advanced HIV disease: evidence for action, Sheraton Boston Hotel, Back Bay Ballroom A, 09:00-11:30

This symposium will summarize the key evidence informing the WHO guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy that will be published as part of a special supplement on advanced HIV disease in Clinical Infectious Diseases on 4th March. Updated guidance on the management of cryptococcal disease to be launched at CROI will be presented.


This meeting will discuss, debate and highlight WHO’s updated and Consolidated Guidelines on the Programmatic Management of Latent TB Infection; research landscapes and options for TB preventive treatment and the new generation of antiretrovirals; and implications for countries and for the design of clinical trials for TB prevention and new antiretroviral drugs. Attendance by registration only.

Monday, March 5, 2018

Plenary PL-1 PLENARY SESSION, 08:30-09:30, Auditorium, Hall C, Auditorium Balcony

09:00 13: Pathogenesis of Tuberculosis and vaccine prevention, Joanne L Flynn

Oral Abstract O-02 ART: NEW DATA AND NEW INSIGHTS
10:00 – 12:00, Auditorium

10:15 23: Impact of Raltegravir intensification of first-line art on IRIS in the REALITY TRIAL, D Gibb
11:30 28LB: Rifampin effect on Tenofovir Alafenamide (TAF) plasma/intracellular pharmacokinetics, M Cerrone
11:40 29LB: Systematic vs test-guided tuberculosis treatment: data of the STATIS randomized trial, F-X Blanc

Oral Abstract O-03 ADVANCES IN TB AND CRYPTOCOCCAL MENINGITIS TREATMENT AND PREVENTION, 10:00 – 12:00, Ballroom C

10:00 31: Effect of TB screening and retention interventions on early ART mortality in Botswana, Andrew F. Auld
10:15 32: A cluster-randomized trial of symptom vs TST screening to improve child IPT uptake, Nicole Salazar-Austin
10:30 33: Safety and efficacy of Dolutegravir-based ART in TB/HIV coinfected adults at week 24, Kelly Dooley
10:45 34: Pharmacokinetics of Bictegravir administered twice daily in combination with Rifampin, Joseph M. Custodio
11:30 37LB: One month of Rifapentine/Isoniazid to prevent TB in people with HIV: BRIEF-TB/A5279, Richard E. Chaisson
11:40 38LB: Urine-based screening for tuberculosis: a randomized trial in HIV-positive inpatients, Ankur Gupta-Wright
11:50 39LB: A randomized controlled trial of high-dose Rifampin for pulmonary tuberculosis, Gustavo E. Velásquez
HIV/TB Roadmap at CROI 2018

Monday, March 5, 2018 continued

Themed Discussion TD-02 CLINICAL PHARMACOLOGY OF HIV-TB COINFECTION, 13:30 – 14:30, Room 304-306
455 Efavirenz pharmacokinetics in HIV/TB coinfected persons receiving Rifapentine, Anthony Podany
456 Efavirenz pharmacokinetics with Rifampin double dose in TB-HIV infected patients, Daniel W. Atwine
457 Pharmacokinetics of Efavirenz 400mg with Isoniazid/Rifampicin in people with HIV, Maddalena Cerrone
458 In silico drug interaction of long-acting Rilpivirine and Cabotegravir with Rifampin, Rajith Kumar Reddy Rajoli

Symposium S-3 OBSTACLES TO THE GLOBAL CONTROL OF TUBERCULOSIS, 16:00 – 18:00, Ballroom C
16:00 56 The global burden of tuberculosis and modeling control strategies, Nimalan Arinaminpathy
16:30 57 Using whole genome sequencing to better understand TB transmission dynamics, Neel R. Gandhi
17:00 58 Undiagnosed tuberculosis: promise for prevention, Neil A. Martinson
17:30 59 New developments in the management of drug-resistant tuberculosis, Serena Koenig

Tuesday, March 6, 2018

Themed Discussion TD-11 THE PERSISTENT CHALLENGE OF LATE PRESENTATION AND MORTALITY, 13:30 – 14:30, Ballroom B
902 Post-hospital mortality and readmission among HIV-infected adults in South Africa, Chris Hoffmann
898 Persons living with HIV with advanced HIV disease: need for novel care models, Chloe A. Teasdale

Wednesday, March 7, 2018

Oral Abstract O-12 CRITICAL ISSUES IN WOMEN’S HEALTH AND EARLY TREATMENT OF PEDIATRIC HIV INFECTION, 10:00 – 12:00, Ballroom C
11:45 142LB Randomized trial of safety of Isoniazid preventive therapy during or after pregnancy, Amita Gupta

Poster Sessions (poster numbers in brackets)
Monday March 5, 14:30-16:00
Poster Hall B
Poster P-R1: Late presentation and mortality: (886-903)

Poster Hall D
Poster P-F1: Antiretroviral, antitubercular, and antimalarial pharmacokinetics: (455-459)
Poster P-Q1: TB incidence, screening, and diagnosis (766-771)
Poster P-Q2: TB biomarkers and inflammation: (772-777)
Poster P-Q3: TB transmission dynamics, drug resistance, and treatment issues: (778-782)
Poster P-Q1: Pharmacokinetics, safety, and uptake of HIV co-treatments in children: (837-839)
Poster P-Q2: Something old, something new: pharmacokinetics and safety of ARVs for infants, children, and adolescents: (845)

Wednesday, March 7, 14:30-16:00
Poster Hall B
Poster P-V3: Tuberculosis, opportunistic infections, and complications: (112-114, 117LB)